The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, IGC Pharma Inc (AMEX: IGC) closed at $0.41 down -0.17% from its previous closing price of $0.41. In other words, the price has decreased by -$0.17 from its previous closing price. On the day, 0.74 million shares were traded. IGC stock price reached its highest trading level at $0.415 during the session, while it also had its lowest trading level at $0.4.
Ratios:
For a deeper understanding of IGC Pharma Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.46 and its Current Ratio is at 1.25. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IGC now has a Market Capitalization of 37243440 and an Enterprise Value of 36525692. For the stock, the TTM Price-to-Sale (P/S) ratio is 28.00 while its Price-to-Book (P/B) ratio in mrq is 5.61. Its current Enterprise Value per Revenue stands at 27.525 whereas that against EBITDA is -5.724.
Stock Price History:
The Beta on a monthly basis for IGC is 1.07, which has changed by 0.13888884 over the last 52 weeks, in comparison to a change of 0.1719923 over the same period for the S&P500. Over the past 52 weeks, IGC has reached a high of $0.50, while it has fallen to a 52-week low of $0.25. The 50-Day Moving Average of the stock is 3.34%, while the 200-Day Moving Average is calculated to be 20.57%.
Shares Statistics:
For the past three months, IGC has traded an average of 3.04M shares per day and 687150 over the past ten days. A total of 84.14M shares are outstanding, with a floating share count of 67.14M. Insiders hold about 26.99% of the company’s shares, while institutions hold 3.30% stake in the company. Shares short for IGC as of 1757894400 were 381667 with a Short Ratio of 0.13, compared to 1755216000 on 1098016. Therefore, it implies a Short% of Shares Outstanding of 381667 and a Short% of Float of 0.5599999999999999.
Earnings Estimates
The firm’s stock currently is rated by 2.0 analysts. The consensus estimate for the next quarter is -$0.02, with high estimates of -$0.02 and low estimates of -$0.02.
Analysts are recommending an EPS of between -$0.08 and -$0.08 for the fiscal current year, implying an average EPS of -$0.08. EPS for the following year is -$0.09, with 2.0 analysts recommending between -$0.08 and -$0.09.
Revenue Estimates
A total of 2 analysts believe the company’s revenue will be $383k this quarter.It ranges from a high estimate of $441k to a low estimate of $325k. As of. The current estimate, IGC Pharma Inc’s year-ago sales were $412kFor the next quarter, 2 analysts are estimating revenue of $316.5k. There is a high estimate of $325k for the next quarter, whereas the lowest estimate is $308k.
A total of 2 analysts have provided revenue estimates for IGC’s current fiscal year. The highest revenue estimate was $1.5M, while the lowest revenue estimate was $1.3M, resulting in an average revenue estimate of $1.4M. In the same quarter a year ago, actual revenue was $1.27MBased on 2 analysts’ estimates, the company’s revenue will be $1.57M in the next fiscal year. The high estimate is $1.65M and the low estimate is $1.5M.
